Related Experiment Video

Updated: Dec 9, 2025

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.0K

Galectin-3: an immune checkpoint target for musculoskeletal tumor patients

Kosei Nakajima1,2, Vitaly Balan3, Avraham Raz4

  • 1Division of Translational Research, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. konakaji@ncc.go.jp.

Cancer Metastasis Reviews
|September 15, 2020
PubMed

Insights

Galectin-3 (Gal-3) is a newly identified immune checkpoint factor. Targeting Gal-3 may offer a novel treatment for aggressive musculoskeletal tumors by enhancing T cell infiltration.

Area of Science:

  • Oncology
  • Immunology
  • Tumor Microenvironment

Background:

  • Immune checkpoint inhibitors have advanced cancer treatment.
  • Musculoskeletal tumors remain underserved by current immunotherapies.

Purpose of the Study:

  • To investigate galectin-3 (Gal-3) as a potential immune checkpoint in musculoskeletal tumors.
  • To explore the relationship between Gal-3 expression and T cell infiltration.

Main Methods:

  • Large-scale cohort study analysis.
  • Evaluation of Gal-3 expression levels.
  • Assessment of T cell infiltration in tumor microenvironments.

Main Results:

  • Overexpression of Gal-3 was prevalent in musculoskeletal tumors.
  • T cell infiltrations were suppressed within the tumor microenvironment.
  • Gal-3 correlates with immune suppression in these tumors.

Conclusions:

  • Galectin-3 acts as an immune checkpoint in musculoskeletal tumors.
  • Targeting Gal-3 presents a novel therapeutic strategy.
  • This approach could improve outcomes for patients with aggressive musculoskeletal tumors.
Keywords:
Bone immunological microenvironmentGalectin-3Immune checkpoint inhibitorMusculoskeletal tumors

More Related Videos

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

16.3K
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.4K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.4K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.2K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
9.8K